Stunnox: when frown lines return

How long a wrinkle treatment “lasts” depends on what is being counted: a completely smooth expression, any improvement, or a return to the starting grade. Those endpoints can tell different stories about the same injection. British Vogue’s 21 October report explores keeping injections private; visibility and duration remain separate research questions.

A study by Sandeep Arora and colleagues, published on 27 October 2026 in Cureus, makes the distinction tangible. It followed Stunnox, a botulinum toxin type A product made by Gufic Biosciences, in Indian adults with mild or moderate frown and forehead lines and Fitzpatrick skin types III–V. This was a single-center, open-label study without a comparison treatment. The manufacturer funded it.

A strong early signal with missing participants

Of 77 people treated, 50 completed the 20-week follow-up. The remaining 27, or 35.1%, were excluded from the efficacy analysis. At the first assessment, week 1, all 50 completers scored zero for both regions on the 0–3 Facial Wrinkle Scale during expression. The study cannot establish the exact day the effect began, and the result cannot be presented as success in all 77 treated participants.

Complete resolution persisted through week 12 for frown lines and week 16 for forehead lines. By week 20, 38% had returned to their starting frown-line grade and 78% to their starting forehead-line grade. Mean scores still remained below baseline: 1.02 versus 1.64 for frown lines, and 0.96 versus 1.18 for forehead lines. A lower average therefore did not mean that most people still had a measurable benefit in both areas.

Duration is not a promise of prevention

The differing results also reflect differing starting severity and treatment protocols. Forehead dosing was fixed; frown-line dosing was individualized. Without a controlled comparison, neither an optimal dose nor superiority over another product can be inferred. One treatment cycle does not show that early injections prevent future fixed wrinkles, an outcome this study did not measure.

Five participants reported brow heaviness lasting four weeks without eyelid drooping; three had transient redness and swelling resolving within 24–48 hours. No serious adverse events were reported, including none reported by noncompleters when contacted. A small, short study cannot exclude uncommon harms.

The full text is available, but availability does not remove the central uncertainty: the 27 missing efficacy records could change the apparent response and durability. The paper also discloses author financial relationships and a coauthor’s affiliation with the manufacturer. The useful message is consequently about interpreting outcomes, not choosing a winning brand: complete resolution, residual improvement and prevention require different evidence.